Poseida Therapeutics, Inc. (NASDAQ:PSTX) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 3,100,000 shares, a decline of 17.8% from the March 31st total of 3,770,000 shares. Approximately 9.2% of the shares of the stock are sold short. Based on an average daily volume of 386,900 shares, the days-to-cover ratio is currently 8.0 days.

Shares of PSTX stock traded down $0.51 during mid-day trading on Tuesday, hitting $8.45. The company had a trading volume of 218,622 shares, compared to its average volume of 359,016. Poseida Therapeutics has a 52-week low of $7.63 and a 52-week high of $17.62. The stock’s 50 day moving average price is $9.41 and its 200-day moving average price is $10.03. The company has a market capitalization of $525.02 million and a P/E ratio of -1.23.

Poseida Therapeutics (NASDAQ:PSTX) last released its quarterly earnings data on Thursday, March 11th. The company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.11. As a group, equities analysts expect that Poseida Therapeutics will post -3 earnings per share for the current year.

Separately, Zacks Investment Research downgraded shares of Poseida Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 17th.

In other Poseida Therapeutics news, insider Matthew A. Spear sold 4,000 shares of Poseida Therapeutics stock in a transaction that occurred on Wednesday, April 21st. The shares were sold at an average price of $8.44, for a total transaction of $33,760.00. Following the transaction, the insider now owns 15,485 shares of the company’s stock, valued at $130,693.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric Ostertag sold 12,389 shares of Poseida Therapeutics stock in a transaction that occurred on Wednesday, February 10th. The shares were sold at an average price of $10.00, for a total transaction of $123,890.00. Following the transaction, the chief executive officer now directly owns 431,590 shares in the company, valued at approximately $4,315,900. The disclosure for this sale can be found here. Insiders have sold 264,538 shares of company stock worth $2,593,750 in the last ninety days. Insiders own 19.03% of the company’s stock.

Several large investors have recently made changes to their positions in PSTX. Strs Ohio bought a new position in shares of Poseida Therapeutics in the 3rd quarter valued at about $30,000. Optimum Investment Advisors bought a new position in shares of Poseida Therapeutics in the 4th quarter valued at about $33,000. Public Employees Retirement System of Ohio bought a new position in shares of Poseida Therapeutics in the 4th quarter valued at about $35,000. JPMorgan Chase & Co. bought a new position in shares of Poseida Therapeutics in the 3rd quarter valued at about $45,000. Finally, Citigroup Inc. lifted its holdings in shares of Poseida Therapeutics by 582.9% in the 4th quarter. Citigroup Inc. now owns 4,405 shares of the company’s stock valued at $48,000 after acquiring an additional 3,760 shares during the last quarter. 41.09% of the stock is owned by hedge funds and other institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC.

Featured Article: How is a buy-side analyst different from a sell-side analyst?

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.